HOME >> MEDICINE >> NEWS
NIAID researchers show how promising TB drug works

Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have determined how a promising drug candidate attacks the bacterium that causes tuberculosis (TB). Published online this week in Proceedings of the National Academy of Sciences, the finding may help scientists optimize the drug candidate, PA-824, which targets Mycobacterium tuberculosis (M. tb).

"PA-824, now in early stage clinical trials, holds promise for shortening the TB treatment regimen, which is currently cumbersome and lengthy," says NIAID Director Anthony S. Fauci, M.D. "This new finding will allow a streamlined approach for making improved versions of the drug."

"Previously, we were flying blind in trying to optimize PA-824 in a rational way because we didn't know which M. tb protein was the target of PA-824's action," says NIAID scientist Clifton Barry, III, Ph.D., who headed the research team.

In preclinical testing, PA-824 showed evidence of being effective against both actively dividing and slow-growing M. tb, giving rise to optimism that the compound may be useful in treating both active and latent TB. (For information about the first clinical trial of PA-824, see June 14, 2005, NIAID press release: http://www3.niaid.nih.gov/news/newsreleases/2005/tb_pa_824.htm.)

PA-824 must be chemically activated in the bacterium before it exerts its anti-tubercular effect, notes Dr. Barry. Earlier research had sketched out the first few steps in this process, but Dr. Barry and his colleagues wanted to pinpoint the precise protein that binds PA-824 and transforms it into a lethal molecule for TB.

The scientists approached the problem indirectly by searching for M. tb mutants that resisted the killing power of PA-824. The team confirmed previous research suggesting that resistance usually occurs when M. tb lacks components
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
26-Dec-2005


Page: 1 2 3

Related medicine news :

1. NIAID releases MDR/XDR Tuberculosis research agenda
2. NIAID DNA vaccine for H5N1 avian influenza enters human trial
3. NIAID media availability: Examining genetic variability of malaria parasite offers insight
4. NIAID awards $4 million to develop anti-radiation treatments
5. Partnership between NIAID and Sequella yields promising new TB drug for clinical testing
6. NIAID announces leadership for newly restructured HIV/AIDS clinical trials networks
7. NIAID study finds higher dose of flu vaccine improves immune response in the elderly
8. NIAID media availability: New study describes key protein from highly pathogenic H5N1 avian flu virus and how it might mutate
9. NIAID media availability: Understanding influenza infection
10. NIAID awards $47 million to develop medical countermeasures against radiological, nuclear threats
11. NIAID launches first Phase II trial of a global HIV/AIDS vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2018)... ... August 31, 2018 , ... Alice Branton shared her personal story ... issues with Daytime host Jerry Penacoli. , With all the medical advancements over ... deficiency is a major public health problem worldwide irrespective of age, location, ethnicity, and ...
(Date:8/31/2018)... ... August 31, 2018 , ... ... an Open House on Wednesday, September 12 from 1:00-3:00 pm. MedMark ... Rapids, as well as tour the facility, meet our staff and learn more ...
(Date:8/31/2018)... Pa. (PRWEB) , ... August 31, 2018 , ... ... those offered by the American Heart Association (AHA) to be responsive for procurement ... concerns and purchasing managers may now reap the benefits. Companies like Pacific Medical ...
(Date:8/31/2018)... SCOTCH PLAINS, N.J. (PRWEB) , ... August 31, ... ... gastroenterologist, Dr. Joseph Savon of South Jersey Gastroenterology for another year. Dr. Savon ... has been one of the leaders in comprehensive care for all gastrointestinal diseases ...
(Date:8/31/2018)... ... August 31, 2018 , ... ... Inc.’s “hit” list. The company, a small molecule drug discovery and development ... September 2017 with a mission to develop a first-in-class therapeutic targeting rare ...
Breaking Medicine News(10 mins):
(Date:9/15/2018)... ... ... "As of Thursday, Sept. 13, 2018, Cedar Point, North Carolina, where I ... Women of Influence tour with the knowledge that my home will have some repairs ... onto my faith through this storm. So many lives are being affected by flood ...
(Date:9/13/2018)... ... September 13, 2018 , ... This September is ... campaign is designed to raise awareness on how to help prevent food poisoning. According ... people) get sick, 128,000 are hospitalized, and 3,000 die from eating contaminated food. In ...
(Date:9/13/2018)... ... 13, 2018 , ... AccentCare, Inc., a nationwide leader in ... regional Texas Home Health operations the largest Texas-based post-acute care provider offering ... care services. , Texas Home Health operations serve all 254 counties in Texas, ...
Breaking Medicine Technology:
Cached News: